These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Metabolic syndrome in patients with schizophrenia: CATIE results. Narasimhan M; Masand P Curr Psychiatry Rep; 2006 Jun; 8(3):213-4. PubMed ID: 19817071 [No Abstract] [Full Text] [Related]
8. Why all GPs should be bothered about Billy. Graham CC; Chitnis AJ; Turner P; Mitchell AJ; Hardy S; Shiers D Br J Gen Pract; 2014 Jan; 64(618):15. PubMed ID: 24567556 [No Abstract] [Full Text] [Related]
9. Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 1: Magnitude and Moderators of the Problem. Andrade C J Clin Psychiatry; 2016 Jul; 77(7):e844-7. PubMed ID: 27464317 [TBL] [Abstract][Full Text] [Related]
11. Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia. Scaini G; Quevedo J; Velligan D; Roberts DL; Raventos H; Walss-Bass C Eur Neuropsychopharmacol; 2018 Mar; 28(3):369-380. PubMed ID: 29449054 [TBL] [Abstract][Full Text] [Related]
12. Managing weight gain and metabolic issues in patients treated with atypical antipsychotics. Henderson DC J Clin Psychiatry; 2008 Feb; 69(2):e04. PubMed ID: 18363448 [TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy? Softic R; Sutovic A; Avdibegovic E; Osmanović E; Bećirović E; Hajdukov MM Psychiatr Danub; 2015 Dec; 27(4):378-84. PubMed ID: 26609650 [TBL] [Abstract][Full Text] [Related]
14. Physical Health and Drug Safety in Individuals with Schizophrenia. Pringsheim T; Kelly M; Urness D; Teehan M; Ismail Z; Gardner D Can J Psychiatry; 2017 Sep; 62(9):673-683. PubMed ID: 28718324 [TBL] [Abstract][Full Text] [Related]
15. Metabolic findings from the CATIE trial and their relation to tolerability. Nasrallah HA CNS Spectr; 2006 Jul; 11(7 Suppl 7):32-9. PubMed ID: 16816798 [TBL] [Abstract][Full Text] [Related]
16. Insulin Resistance in Schizophrenia. Guest PC Adv Exp Med Biol; 2019; 1134():1-16. PubMed ID: 30919329 [TBL] [Abstract][Full Text] [Related]
17. Prevention of metabolic syndrome from atypical antipsychotic medications: applying Rogers' diffusion of innovations model in clinical practice. Parrinello MC J Psychosoc Nurs Ment Health Serv; 2012 Dec; 50(12):36-44. PubMed ID: 23457716 [TBL] [Abstract][Full Text] [Related]
18. Metabolic comorbidity in schizophrenia. Jacob R; Chowdhury AN Indian J Med Sci; 2008 Jan; 62(1):23-31. PubMed ID: 18239269 [TBL] [Abstract][Full Text] [Related]
19. Obesity, diabetes, and the metabolic syndrome: new challenges in antipsychotic drug therapy. Caballero E CNS Spectr; 2003 Nov; 8(11 Suppl 2):19-22. PubMed ID: 14978454 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Krane-Gartiser K; Breum L; Glümrr C; Linneberg A; Madsen M; Køster A; Jepsen PW; Fink-Jensen A Nord J Psychiatry; 2011 Oct; 65(5):345-52. PubMed ID: 21428861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]